MedTrace Logo

Impact of MK-0518 (Raltegravir) Intensification on HIV-1 Viral Latency in Patients With Previous Complete Viral Suppression

NCT00554398 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2019-12-04

No results posted yet for this study

Summary

An intensification with the HIV-1 integrase inhibitor Raltegravir (RAL) of a stable HAART regimen with persistent HIV-1 viral suppression could increase the slope of decay of the HIV-1 latent reservoir.

Conditions

  • HIV Infections

Interventions

DRUG

MK-0518 400mg twice a day

Raltegravir, MK-0518

Sponsors & Collaborators

  • Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

    collaborator OTHER

  • Germans Trias i Pujol Hospital

    lead OTHER

Principal Investigators

  • Martínez-Picado Javier, MD,PhD · Irsi Caixa -Hospital Germans Trias i Pujol

  • Paredes Roger, MD,PhD · Lluita contra la Sida Foundation

  • Clotet Bonaventura, MS,PhD · Lluita contra la Sida Foundation

  • Llibre Josep Mª, MD,PhD · Lluita contra la SIDA Foundation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-05-31
Completion
2009-09-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00554398 on ClinicalTrials.gov